Geka Pharma Pvt Ltd.
Business Opportunity Assessment Report

Company Snapshot

Geka Pharma Pvt Ltd. is a Namibian-registered private pharmaceutical trading entity, primarily engaged in the import and distribution of finished dosage form medicines and healthcare products across Southern Africa. It operates as a specialized distributor—neither a manufacturer nor a brand owner—with supply chain integration focused on regulatory-compliant procurement and regional logistics coordination. Its trade structure is highly concentrated: over 94% of transactions occur with South African partners, and HS codes 30049099 (other medicaments) and 30033900 (combined hormonal contraceptives) dominate its import profile. A notable shift occurred in late 2024–2025, when monthly transaction volumes dropped sharply from peaks exceeding 240,000 units (Jan–Feb 2024) to sub-8,000 units (Nov–Dec 2025), signaling a structural contraction or operational recalibration.

Company Attribute Information

Trade Trend Analysis

Data解读: Transaction volume exhibits extreme volatility — a >96% decline from 240,802 units in February 2024 to just 720 units in December 2025 — indicating either a strategic pivot, regulatory suspension, or temporary market exit; the concurrent stability in transaction count (1,024–1,373 per month since mid-2024) suggests consolidation into fewer, larger orders rather than full cessation. The drop coincides with no visible corporate updates or digital footprint, raising questions about operational continuity. Risk perspective: High uncertainty due to abrupt volume collapse without public explanation or active online presence.

Trade Partner Analysis

Data解读: Geka Pharma’s partner network is deeply anchored in Southern Africa’s pharmaceutical ecosystem — 13 of top 20 partners are South African firms (including Novartis SA, Pfizer Labs, Sandoz SA), and Indian multinationals (Adcock Ingram, Roche India) serve as key upstream suppliers. The absence of Namibian domestic partners and zero visibility of local manufacturing links confirm its role as an import-distribution conduit rather than a locally integrated player. Risk perspective: Overreliance on South Africa (>94% of trade) creates acute geopolitical, regulatory, and logistical exposure.

HS Code Analysis

Data解读: HS 30049099 (‘Other medicaments’) accounts for 36.9% of all transactions — a broad residual category covering unclassified finished pharmaceuticals — while HS 30033900 (hormonal contraceptives) captures 26.3%, revealing a clear therapeutic focus on reproductive health and chronic disease management. The presence of diagnostic-related codes (90189000, 38221900) and excipients (21069090, 22060090) signals value-added distribution involving formulation support and kit assembly. Risk perspective: Heavy concentration in two HS codes increases vulnerability to regulatory scrutiny or tariff adjustments in contraceptive and generic medicine categories.

Trade Region Analysis

Data解读: South Africa alone constitutes 94.4% of total transaction count — a near-monopoly in geographic sourcing — while Botswana (2.85%) and Germany/UAE/Kenya (<0.3% each) represent marginal diversification efforts. The ‘other’ and ‘Costa Rica’ entries marked ‘lost’ since Jan 2024 suggest deliberate withdrawal from non-core markets, reinforcing a hyper-regionalized strategy tightly coupled to South African regulatory approvals and distribution networks. Risk perspective: Near-total dependency on one country severely limits resilience to policy shifts, port delays, or bilateral trade friction.

Export Port Analysis

No export port data available in source material.

Contact Information

No verifiable official website, email, phone number, or social media profile (LinkedIn, Facebook, Twitter) was identified through targeted search. No Wikipedia entry, press release, or corporate news coverage exists. All search results returned unrelated content (e.g., Microsoft Word tutorials, Honda vehicle listings), confirming zero digital footprint.

Company Trade Summary

• Operates exclusively as a pharmaceutical distributor — no evidence of manufacturing, branding, or retail activity.
• Trade is overwhelmingly concentrated in South Africa (94.4%) and two HS codes (30049099 + 30033900 = 63.2% of all transactions).
• Transaction volume collapsed >96% from early 2024 to late 2025 — yet transaction frequency remained stable, suggesting order consolidation or operational pause.
• Zero digital presence and no public contact information raise material transparency and reliability concerns.
• No customs export port data available — consistent with its role as importer/distributor, not exporter.